Creating new chiral small molecules for drug development
Enantioenriched Nitrogen-Containing Small Molecules via Stereoselective Carbon-Carbon Bond Construction
This study is exploring new ways to create special tiny molecules that can help make better medicines, which could lead to new drugs that work more effectively and safely for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Wilmington NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project ID | NIH-10973829 on NIH RePORTER |
What this research studies
This research focuses on developing new methods to synthesize chiral nitrogen-containing small molecules, which are crucial for creating effective pharmaceuticals. The approach involves using advanced chemical techniques, such as ring opening of aziridines and epoxides, to produce these molecules in a stereoselective manner. By employing chiral Lewis acid catalysis, the researchers aim to enhance the efficiency of carbon-carbon bond formation, ultimately leading to the discovery of novel drugs. Patients may benefit from this research as it could lead to the development of new medications with improved efficacy and safety profiles.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would be individuals with conditions that could be treated by new nitrogen-containing pharmaceuticals.
Not a fit: Patients who are not seeking new medication options or those with conditions that do not respond to nitrogen-containing drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the creation of more effective and safer medications for various health conditions.
How similar studies have performed: Other research has shown success in developing chiral small molecules using similar stereoselective methods, indicating a promising avenue for drug development.
Where this research is happening
Wilmington, United States
- University of North Carolina Wilmington — Wilmington, United States (Active)
Researchers
- Principal investigator: Morgan, Jeremy B — University of North Carolina Wilmington
- Study coordinator: Morgan, Jeremy B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.